Tag: LINC 2019
Paclitaxel-releasing devices: An unfolding story
Paclitaxel Timeline:
Meta-analysis finds a higher risk of death in the long term when paclitaxel-coated devices are used in the leg
Without additional long-term...
US FDA continues to investigate paclitaxel devices in the leg
A meta-analysis published in the Journal of the American Heart Association (JAHA) late last year by Konstantinos Katsanos (Patras, Greece) and colleagues, suggesting an...
Two companies with paclitaxel-coated devices issue corrections to published data
Both Medtronic and Cook Medical have issued corrections to published data regarding the safety of their paclitaxel-coated devices. While Medtronic have revised IN-PACT post-market...
Medtronic revises IN.PACT post-market study data due to programming error, but...
Medtronic has issued the following statement regarding revised clinical study data:
Recently, Medtronic became aware of a programming error in the clinical data reporting isolated...
SIBERIA trial: Positive one-month results for embolic prevention system
InspireMD has announced positive interim results from the SIBERIA trial, an investigator-initiated study of the CGuard embolic prevention system (EPS). The data were presented...
ULTRASCORE scoring helps obtain luminal gain at low inflation pressure before...
Dierk Scheinert (Leipzig, Germany) talks to Vascular News at LINC 2019 about the importance of vessel preparation with adjunctive therapies such as the use...
New data release at LINC 2019 reinforces safety profile of low-dose...
Sean Lyden (Cleveland, USA) and Fabrizio Fanelli (Rome, Italy) discuss the safety and future of drug-coated balloons (DCB) in light of the latest pooled...
Patient-level analysis shows no correlation between paclitaxel and mortality—reactions from LINC
Renowned experts expressed confidence in the continued use of paclitaxel-coated devices after independent patient-level data presented at LINC 2019 did not show correlation between...
Three-year Japanese results show IN.PACT Admiral DCB offers “consistent and durable”...
The IN.PACT Admiral drug-coated balloon (DCB; Medtronic) exhibits a consistent and durable treatment effect in “a more complex patient demographic than typically seen in...
Gore Tigris vascular stent demonstrates high patency rates at 12 months
New results suggest that the Tigris vascular stent (Gore) is a safe and effective device that can be incorporated into a modern “leave-nothing-behind” treatment...
Latest data from Philips reinforces the safety profile of Stellarex low-dose...
A new pooled analysis of patient-level data from Philips demonstrates the “strong safety profile” of the its Stellarex drug-coated balloon (DCB) in above-the-knee studies,...
IN.PACT independent patient-level meta-analysis shows no correlation between paclitaxel exposure and...
A renowned panel, moderated by Dierk Scheinert (Leipzig, Germany), comprising Peter Schneider (Honolulu, USA), John Laird (St Helena, USA) and Thomas Zeller (Bad Krozingen,...
Patient-level survival analysis demonstrates no link between paclitaxel dose and mortality...
New data on the IN.PACT Admiral drug-coated balloon (DCB; Medtronic) in patients with peripheral arterial disease (PAD) in the superficial femoral (SFA) and popliteal...
Data presented at LINC confirm the safety and effectiveness of Zilver...
Findings presented at the Leipzig Interventional Course (LINC; 22–25 January 2019, Leipzig, Germany) contradict the results of a meta-analysis published in the Journal of...
